Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Settings
Language
ENGLISH
Currency
USD
Theme
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rank in Stocks #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Share Price
$0.00047446
Market Cap
$82.80
Change (1 day)
0.00%
Change (1 year)
-98.16%
Country
FR
Trade Neovacs S.A. (ALNEV)

Category

Healthcare
P/S ratio for Neovacs S.A. (ALNEV)
P/S ratio as of April 2026 TTM: 0.00
According to Neovacs S.A. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 1.32K.
P/S ratio history for Neovacs S.A. from 2007 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 -100.00%
2024 485.89 -63.15%
2023 1.32K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.54 707,620.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.38 1,874,940.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.47 1,094,520.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.65 1,330,780.00%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
15.23 3,045,540.00%
NL